Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.
Antegren
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2010
2010
Natalizumab (Tysabri®, formerly known as Antegren®, Elan Pharmaceuticals [Elan; San Francisco, CA, USA] and Biogen Idec [Biogen… Expand
2004
2004
In this open-label drug-interaction trial, we studied 38 patients with relapsing-remitting multiple sclerosis (MS) who received 3… Expand
Highly Cited
2004
Highly Cited
2004
Natalizumab (Antegren™, Elan Corp. plc.; Biogen Idec.) is the first α4-integrin antagonist in the class of selective adhesion… Expand
Review
2004
Review
2004
Natalizumab (Antegren, Elan Corp. plc.; Biogen Idec.) is the first alpha4-integrin antagonist in the class of selective adhesion… Expand
Review
2004
Review
2004
Natalizumab [AN 100226, anti-alpha4 integrin monoclonal antibody, Antegren] is a humanised monoclonal antibody that blocks… Expand
2002
2002
ZusammenfassungAntegren (Natalizumab) ist ein “humanisierter” monoklonaler Antikörper, der an die α4-Untereinheit von α4β1… Expand
2002
2002
Antegren (Natalizumab) is a humanized monoclonal antibody directed against alpha 4-integrin. This antibody binds to the alpha 4… Expand
Highly Cited
1999
Highly Cited
1999
Objective: To determine the effect of humanized monoclonal antibody against α4 integrin (reactive with α4β1 integrin or very-late… Expand
Highly Cited
1999
Highly Cited
1999
OBJECTIVE
To determine the effect of humanized monoclonal antibody against alpha4 integrin (reactive with alpha4beta1 integrin or… Expand
1998
1998
AN-100226 (Antegren), a humanized monoclonal antibody (MAb) directed against the alpha4beta1 integrin (VLA-4) expressed on… Expand